Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Brokerages
Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price […]
Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price […]
